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ABSTRACT The stability and tissue distribution of lipid ves-
icles modified at the surface by the incorporation ofeither a galac-
tosyl ceramide (GalCer)'or a galactosyl'cholesterol (GalChol) gly-
coconjugate have been studied in. mice by measuring the release
of vesicle-entrapped "'1In. Although the tissue distributions of
both vesicle types were similar, the GalCer-containing vesicles
were markedly less stable than those. prepared with GalChol,
whether administered orally or by intraperitoneal injection. Phys-
ical characterization of the vesicles in vitro suggests that the in-
creased disruption rate for GalCer vesicles in vivo is related to.
structural instabilities induced by the cerebroside, which can then
result in either an increased rate of vesicle uptake by tissues or
a greater susceptibility to lysis. These studies demonstrate the im-
portance ofthe nonpolar anchoring groups in determining the fate
of surface-modified vesicles in vivo.
The targeting ofencapsulated agents, such as drugs or enzymes,
to specific tissues is one of the goals in the development of lip-
osomes as exogenous delivery systems. To achieve this result,
a number of strategies have been attempted, including the ad-
dition ofcharged lipids to neutral vesicles (1), the covalent bind-
ing of antibodies to vesicle surfaces (2), and the use of localized
hyperthermia to induce phase transitions in synthetic liposomes
(3). The finding that mammalian hepatocyte surfaces contain a
galactose-specific glycoprotein binding site (4) has led to studies
on the usefulness ofcarbohydrate-modified vesicles in targeting
encapsulated materials (5-7). Initial work has shown great
promise (7), leading to further investigation ofvariables that can
affect the system.
Due to the amphiphilic nature of vesicle bilayers, it is con-
venient to incorporate polar carbohydrate molecules by attach-
ing them to nonpolar lipid groups. In view' of the importance
of lipid shape to vesicle structure (8), it is likely that the choice
of lipid conjugate or anchoring group will, in addition to the
type of carbohydrate used, affect the fate of modified vesicles
in vivo. In the present communication; we report studies of
carbohydrate-modified vesicles containing glycolipids differing
in the structure oftheir nonpolar group. The results, comparing
the effects of N-stearoyl-DL-dihydrogalactocerebroside (galac-
tosyl ceramide, GalCer, II) with those of 6-(5-cholesten-3f-
yloxy)hexyl-l-thio-(3-D-galactopyranoside (galactosyl choles-
terol, GalChol, I) demonstrate the importance of the carbo-
hydrate anchoring group in maintaining stable vesicles in vivo.
MATERIALS AND METHODS
Materials. L-a-Distearoylphosphatidylcholine from Calbi-
ochem and cholesterol from Sigma were used without further
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purification. GalChol was synthesized at Merck. GalCer was
purchased from Miles. GalCer and GalChol were labeled at the
C-6 position of galactose, with tritium or deuterium, by the
method ofSuzuki and Suzuki (9) using NaB3H4 (specific activity,
350 Ci/mol; 1 Ci = 3.7 x 1010 becquerels) from ICN and
NaB2H4 (98 atom % 2H) from Merck. The trisodium salt of nit
trilotriacetic acid was purchased from Aldrich and ultrapure
InCl3 was obtained from Ventron (Danvers, MA). 111InCl3 was
purchased from Medi+Physics (Glendale, CA) and purified
according to the method of Hwang and Mauk (10). The iono-
phore A23187 was a gift from Eli Lilly.
Preparation of Vesicles. Small unilamellar vesicles, pre-
pared according to the method of Mauk and co-workers (6, 7,
10-12), were composed of L-a-distearoylphosphatidylcholine,
cholesterol, glycoconjugate (GalChol or GalCer), and A23187
at 2:0.5:0.5:0.004 (mol/mol).
Electron Microscopy. Vesicle size distributions were deter-
mined by electron microscopy offresh preparations, negatively
stained with 2% phosphotungstic acid as described by Sheetz
and Chan (13).
Vesicle Stability in Vivo. Vesicles containing "11In3+ were
administered to Swiss-Webster mice (18-22 g) orally or intra-
peritoneally (i.p.). "11In3+ permeability was monitored by the
y-ray perturbed- angular correlation technique (6, 7, 10-12).
The tissue distribution of radioactivity was determined' by as-
saying samples in a well-type y-ray spectrometer (7).
Studies in Vitro. Vesicle thermolability in serum was mea-
sured by the y-ray perturbed angular correlation technique,
Abbreviations: i.p., intraperitoneal; GalChol, galactosyl cholesterol, 6-
(5-cholesten-3,8-yloxy)hexyl-l-thio-f3-D-galactopyranoside; GalCer,
galactosyl ceramide, N-stearoyl-DL-dihydrogalactocerebroside.
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FIG. 1. Stability of vesicle preparations in live mice administered
by i.p. injection (A) or orally (B). o, GalChol-containing vesicles; A,
GalCer-containing vesicles.
as described (14). Vesicle aggregation and fusion in buffered so-
lution was monitored by light scattering (15). 2H NMR spectra
were obtained with a Bruker WM 500 spectrometer equipped
with a BVT 1000 variable-temperature controller.
RESULTS
In Vivo Studies. Thirty hours after oral administration, ap-
proximately half of the GalChol-containing vesicles are intact,
while less than 20% of the vesicles prepared with GalCer have
retained their contents (Fig. 1B). Similarly, when vesicles are
injected i.p., the breakdown rate of GalCer vesicles is more
rapid than that of GalChol vesicles, which change very slowly
after 40 hr (Fig. 1A). This differential breakdown rate is also
reflected in the time course for urinary excretion of 3H-labeled
galactose. As shown in Fig. 2B, after oral administration of
GalCer vesicles, the bulk of the labeled material appears in the
urine in approximately 5 hr while, for the GalChol vesicles, the
peak in excretion of labeled material is reached almost 3 hr later.
A markedly different pattern emerges when vesicles are ad-
ministered by i.p. injection. In this case, the peak in excretion
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Table 1. Tissue distribution of "'In-labeled vesicles
Oral administration* i.p. Administration
GalChol GalCer GalChol GalCer
Stomach 46.1% 58.9% Liver 31.4 31.3
Large intestine 34.1 12.7 Skin 12.5 9.4
Small intestine 5.6 4.5 Pelvic tissue 11.2 9.4
Pelvic tissue 5.6 3.3 Abdomen 10.6 7.2
Legs 2.3 3.0 Small intestine 7.3 9.2
Skin 1.7 3.6 Kidney 8.4 7.5
Liver 1.6 5.7 Legs 5.4 4.6
Kidney 1.4 5.9 Blood 4.1 11.5
Abdomen 0.9 1.7 Large intestine 3.0 2.4
Blood 0.5 0.3 Spleen 2.5 2.4
Heart 0.2 0.2 Stomach 1.5 2.6
Spleen 0.06 0.2 Lung 1.5 1.9
Heart 1.0 0.9
* Lung tissue was not included.
of labeled material for GalCer-injected mice is not reached until
30 hr while, with GalChol vesicles, little or no labeled material
is ever present, even after 80 hr.
In agreement with previous studies (7, 11), it was found that
the method of administration also has a significant effect on the
tissue distribution (Table 1). Most of the "'1In was found in the
stomach and intestines, 24 hr after oral administration, while
i.p. injection resulted in a wider distribution with about a third
of the vesicle material located in the liver. In comparing the
results for the carbohydrate-modified vesicles, it was found
that, when administered by the same route, there is a remark-
able similarity in the tissue distribution, despite the marked
difference in stability. The major difference after oral admin-
istration appears in the distribution between stomach and large
intestine, with more material from the unstable GalCer vesicles
being retained in the stomach and less found in the large in-
testine. i.p. injection showed only a slight difference in the
amounts of material found in the blood, the difference for all
other tissues being insignificant.
In Vitro Studies. To gain some insight into the mechanism
responsible for the variability ofvesicle stability in vivo, a num-
ber ofexperiments were carried out in vitro. The thermolability
of carbohydrate-modified vesicles in serum is shown in Fig. 3.
As with the studies carried out in mice, the GalCer vesicles are
much less stable than the GalChol vesicles. In related work, the
binding of serum proteins to vesicles was measured and found
to be identical for the two types of vesicles. The amount bound
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FIG. 2. Time course of urinary excretion of [3H]galactose after i.p. injection (A) or oral administration (B) of vesicles containing [3H]GalChol
(e) or [3H]GalCer (A).
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FIG. 3. Thermolability of galactose-modified vesicles in serum.
*, GalChol-containing vesicles; A, GalCer-containing vesicles.
was less than 1/10th the value found for control vesicles without
carbohydrates (unpublished data). These results suggest that
the observed instability of GalCer vesicles is an inherent prop-
erty. This. possibility is further supported by the results from
light-scattering experiments shown in Fig. 4. The increased
scatter seen after sonication of the GalCer vesicles in buffer in-
dicates that they are either aggregating or undergoing fusion
to form larger vesicles at a faster rate than are the GalChol ves-
icles (15, 16).
DISCUSSION
The use of lipid bilayer vesicles to deliver exogenous agents to
specific organs and tissues is one of the more recent efforts in
the development of therapeutically targeted agents (17). How-
ever, the vesicle approach has several promising advantages,
not the least of which is that, once the method has been per-
fected, practically anything can be delivered to a specific site.
Of more current usefulness, in the development of this tech-
nique, is the variety ofways in which the vesicles can be mod-
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FIG. 4. Change in turbidity of galactose-modified vesicle prepa-
rations stored at 370C. e, GalChol-containing vesicles; A, GalCer-con-
taining vesicles.
ified. Since the objective is to bring vesicles together with the
membrane surfaces of specific types of cells, most of the initial
approaches have involved alterations in the outer surfaces ofthe
vesicles (1, 2, 5-7). It is also, ofcourse, important that the mod-
ification not significantly decrease the stability of the vesicle
before it reaches the target.
Figs. 1 and 2 and Table 1 present evidence showing that there
is a marked difference in the relative stabilities in vivo of ga-
lactose-modified vesicles that differ in the structures of their,
hydrophobic lipid groups. In general, such differences can be.
caused by a variation in either the rate of vesicle uptake by tis-
sues or the rate of vesicle lysis, a process that could also be oc-
curring extracellularly. The latter possibility is supported by the
similar results found when vesicles are administered by two
different routes, i.p. and oral, that expose them to different
biochemical environments. Further evidence that the instabil-
ity of GalCer vesicles, relative to that of GalChol vesicles, is an
inherent property, is shown in Fig. 4, where marked differences
....
FIG. 5. Electron micrographs of negatively stained vesicle preparations. (Left) GalChol-containing vesicles (average diameter, 662 + 60 A).(Right) GalCer-containing vesicles (average diameter, 639 ± 60 A). (x 13,900.)
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FIG. 6. Temperature dependence on the deuterium linewidth aris-
ing from 2H-labeled galactose conjugates in chloroform/methanol
(1.5:1.0). e, GalChol; A, GalCer.
are observed for the rates of spontaneous aggregation and fu-
sion. Significantly, these data also show that the decreased sta-
bility of GalCer-modified vesicles in buffer at 370C occurs
within the same time period found for the instability in vivo
(see Fig. 1).
The spontaneous aggregation and fusion of neutral phospho-
lipid vesicles has been studied in some detail and is believed
to be caused by structural instabilities brought on by the packing
requirements for bilayer lipids to form small unilamellar vesi-
cles (15, 16). Because the initial sizes of the two types ofvesicles
are similar (Figs. 4 and 5), the shapes of the individual lipid
molecules present must be compatible with the packing re-
quirements for these structures (8). Thus, we can assume that,
immediately after sonication, the free energies of the two types
of vesicles are similar (18) and that the increase in the relative
rate of aggregation or fusion seen for GalCer vesicles is due to
a reduction in the small energy barrier stabilizing them. This
reduction in stability is likely to be caused by the formation of
more packing defects in the GalCer vesicles than in the GalChol
vesicles. However, because ofthe initial size similarity, the lipid
packing should also be similar. One mechanism for introducing
additional packing instabilities after sonication is the formation
by the cerebrosides of stable complexes that result in a net re-
duction in the bilayer volume.
Indirect evidence for the formation of hydrogen-bonded cer-
ebroside complexes has been reported in unsonicated phos-
pholipid bilayers (19). We have obtained direct evidence for the
formation of GalCer aggregates, which are more stable than
GalChol aggregates, from 2H NMR studies of deuterium-la-
beled glycolipids in nonaqueous solvents. The aggregation of
amphiphiles in such a system depends strongly on their head-
group structure (20) and serves as a convenient model for com-
paring the polar interactions of lipids dissolved in a bilayer. For
relatively rapid motions, the linewidth of the deuterium signal
is determined by the molecular tumbling rate (21), which in turn
depends on the aggregate size. Thus, from measurement of the
linewidth, one can monitor changes in the average size of the
lipid aggregates. These studies, in which both solvent polarity
and temperature were varied, show that a marked difference
exists in the aggregation states of the two glycolipids. The for-
mation of a relatively stable aggregate by the cerebroside in
chloroform/methanol (1.5:1.0) is shown in Fig. 6. The Ar-
rhenius plots indicate an energy barrier of 4.1 kcal/mol (1 cal
= 4.18 J) for the GalCer micelles and one of 1.9 keal/mol for
GalChol. For comparison, the activation energy for phospha-
tidycholine micelles in chloroform/water is only 0.46 kcal/mol
(22). In pure chloroform, GalCer was practically insoluble while
the GalChol aggregates became much larger. The observation
that GalCer forms complexes in phospholipid bilayers (19) cor-
relates with the relatively high activation energy reported here
for GalCer aggregates. The lower activation energy found for
GalChol aggregates suggests that formation of GalChol com-
plexes in the bilayer plane is less likely. These data further sup-
port, but do not confirm, the possibility that lipid-lipid inter-
actions are responsible for the reduced stability of GalCer-
containing vesicles.
The studies presented here provide evidence that galactose-
modified cerebrosides reduce the stability of phospholipid/
cholesterol vesicles, both in vivo and in vitro. Similarly mod-
ified vesicles, prepared with a galactose-cholesterol conjugate,
show much greater stability. The effects ofthe cerebrosides may
result from complex formation within the plane of the bilayer.
This process could be useful for the timed release of labile mol-
ecules from vesicles. However, and perhaps more significantly,
this work also shows the importance of the lipid-anchoring
group in maintaining vesicle stability and further indicates that
cholesterol conjugates are preferable for the formation of stable
carbohydrate-modified vesicles.
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